| Market Capitalization (Millions $) |
4,921 |
| Shares
Outstanding (Millions) |
149 |
| Employees |
927 |
| Revenues (TTM) (Millions $) |
954 |
| Net Income (TTM) (Millions $) |
-319 |
| Cash Flow (TTM) (Millions $) |
-67 |
| Capital Exp. (TTM) (Millions $) |
67 |
Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals Inc is a biopharmaceutical company that has its headquarters in Carlsbad, California, United States. The company's main focus is on the development of RNA-targeted therapeutics which can help in treating various diseases. The company has been in operation since 1989 and it was formerly known as Isis Pharmaceuticals. It changed its name to Ionis Pharmaceuticals in December 201
Ionis Pharmaceuticals has a unique therapeutic approach that involves the development of antisense drug candidates, which are designed to target RNA molecules in the body. The company has a wide range of research and development programs that are focused on developing drugs for different diseases. Some of these diseases include neurological disorders, cardiovascular diseases, and various types of cancer.
One of the company's most well-known products is Spinraza, which is a drug that treats spinal muscular atrophy (SMA). SMA is a genetic disorder that causes progressive muscle weakness and it is one of the leading causes of infant mortality. Spinraza was approved by the US Food and Drug Administration (FDA) in December 2016, and it is now widely used in the treatment of SMA.
In addition to Spinraza, Ionis Pharmaceuticals has several other drugs in clinical development. These drugs include drugs for the treatment of Huntington's disease, cardiovascular disease, and cancer. The company has also been able to establish several collaborations with other pharmaceutical companies, which has helped to leverage its antisense technology to create more effective drugs.
Ionis Pharmaceuticals has a strong financial position and has been able to raise significant amounts of capital over the years. The company's revenue is mainly generated from royalties, licensing fees, and milestone payments from its partnerships. In 2020, the company generated $192 million in revenue, a significant increase from the previous year.
In conclusion, Ionis Pharmaceuticals Inc is a biopharmaceutical company that has gained recognition for its unique approach to RNA-targeted therapeutics. The company's innovative products have shown promising results in the treatment of various diseases, and with its strong financial position, it is well positioned to continue developing cutting-edge therapies in the future.
Company Address: 2855 Gazelle Court Carlsbad 92010 CA
Company Phone Number: 931-9200 Stock Exchange / Ticker: NASDAQ IONS
|
3.73% 